Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

67.05USD
16 Feb 2018
Change (% chg)

$-1.05 (-1.54%)
Prev Close
$68.10
Open
$67.55
Day's High
$69.05
Day's Low
$66.25
Volume
166,179
Avg. Vol
264,915
52-wk High
$136.90
52-wk Low
$28.35

Latest Key Developments (Source: Significant Developments)

Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement
Thursday, 1 Feb 2018 04:15pm EST 

Feb 1 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA.PUMA BIOTECHNOLOGY - CANBRIDGE WILL DEVELOP AND COMMERCIALIZE NERLYNX (NERATINIB) IN MAINLAND CHINA, TAIWAN, HONG KONG, AND MACAU.PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT PAYMENT OF $30 MILLION.PUMA BIOTECHNOLOGY - CO TO GET UPFRONT PAYMENT OF $30 MILLION AND POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $40 MILLION.PUMA BIOTECHNOLOGY - TO GET SIGNIFICANT DOUBLE-DIGIT ROYALTIES ON NERLYNX SALES IN GREATER CHINA AND POTENTIAL MILESTONE PAYMENTS.  Full Article

Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib
Tuesday, 23 Jan 2018 04:15pm EST 

Jan 23 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER.PUMA BIOTECHNOLOGY - CHMP USE OF EMA COMMUNICATED NEGATIVE TREND VOTE AFTER MEETING WITH CO TO DISCUSS MAA FOR NERATINIB​.PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE MEANS IT IS UNLIKELY CHMP WILL PROVIDE POSITIVE OPINION RELATED TO MAA AT FORMAL DECISION VOTE IN FEB. 2018.PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE ALSO MEANS ADDITIONAL STEPS WOULD NEED TO BE TAKEN TO GAIN MARKETING APPROVAL IN EUROPE.PUMA BIOTECHNOLOGY - CHMP INDICATED BENEFIT RISK ASSESSMENT NEGATIVE AS STUDY RESULTS BASED ON EVIDENCE FROM SINGLE PIVOTAL TRIAL, AMONG OTHER THINGS.PUMA BIOTECH -CHMP INDICATED BENEFIT RISK ASSESSMENT ALSO NEGATIVE AS 2- & 5-YEAR IDFS BENEFITS OBSERVED TO-DATE MAY LACK SUFFICIENT CLINICAL RELEVANCE.  Full Article

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings
Monday, 11 Dec 2017 08:45am EST 

Dec 11 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS.PUMA BIOTECHNOLOGY - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG.  Full Article

PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA
Wednesday, 22 Nov 2017 09:15am EST 

Nov 22 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA.PUMA BIOTECHNOLOGY INC - ‍PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS OF UP TO $4.5 MILLION THROUGHOUT TERM OF THE AGREEMENT​.PUMA BIOTECHNOLOGY-SPECIALISED THERAPEUTICS RESPONSIBLE FOR SEEKING REGULATORY APPROVALS, FOR COMMERCIALIZING NERLYNX IN SOUTH EAST ASIAN COUNTRIES.PUMA BIOTECHNOLOGY INC - ‍EXPECT TO HAVE REGULATORY APPROVAL FOR NERLYNX IN AUSTRALIA BY Q2 OF 2019​.  Full Article

Puma Biotechnology reports Q3 adj. loss per share $1.36
Thursday, 9 Nov 2017 04:07pm EST 

Nov 9 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology reports third quarter 2017 financial results.Q3 adjusted non-GAAP loss per share $1.36.Q3 earnings per share view $-2.58 -- Thomson Reuters I/B/E/S.Q3 loss per share $2.07.  Full Article

Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance
Thursday, 2 Nov 2017 04:20pm EDT 

Nov 2 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance.Puma Biotechnology - ‍proceeds from financing will be used to continue to support Nerlynx commercial activities, ongoing research with neratinib ​.  Full Article

Puma Biotechnology reports Q2 loss per share $2.10
Wednesday, 9 Aug 2017 04:20pm EDT 

Aug 10 (Reuters) - Puma Biotechnology Inc -:Puma Biotechnology reports second quarter 2017 financial results.Q2 adjusted non-gaap loss per share $1.38.Q2 earnings per share view $-2.04 -- Thomson Reuters I/B/E/S.Q2 loss per share $2.10.Puma Biotechnology Inc - ‍anticipate that primary analysis of data related to nala trial will be available during first half of 2018​.  Full Article

U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer
Monday, 17 Jul 2017 05:36pm EDT 

July 17 (Reuters) - Puma Biotechnology Inc :U.S. Food and Drug Administration approves Puma's Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early stage breast cancer.Puma Biotechnology Inc - expects Neratinib to become commercially available in September 2017 and to be marketed as Nerlynx.  Full Article

Puma Biotechnology completes targeted enrollment in Neratinib Phase III metastatic breast cancer trial
Thursday, 6 Jul 2017 04:15pm EDT 

July 6 (Reuters) - Puma Biotechnology Inc ::Puma biotechnology completes targeted enrollment in neratinib phase iii metastatic breast cancer trial.Puma biotechnology inc says company anticipates that primary analysis of pfs will be available during first half of 2018.  Full Article

Partner Fund Management reports 8.1 pct passive stake in Puma Biotechnology
Monday, 5 Jun 2017 04:30pm EDT 

June 5 (Reuters) - Puma Biotechnology Inc : :Partner Fund Management LP reports 8.1 percent passive stake in Puma Biotechnology Inc as of May 24 .  Full Article

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage: